NasdaqGS - Delayed Quote USD
Kiniksa Pharmaceuticals International, plc (KNSA)
Tune into earnings calls Now streaming directly on quote pages.
25.88
+4.41
+(20.54%)
At close: April 29 at 4:00:01 PM EDT
26.49
+0.61
+(2.36%)
After hours: April 29 at 7:54:34 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 341,650 | 34 |
| Sales | 333,547 | 15 |
| Net Shares Purchased (Sold) | 8,103 | 49 |
| Total Insider Shares Held | 2.93M | -- |
| % Net Shares Purchased (Sold) | 0.30% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| MOAT ROSS Officer | Sale at price 20.29 per share. | Direct | 370,475 | Apr 21, 2025 |
| TESSARI EBEN Chief Operating Officer | Conversion of Exercise of derivative security at price 3.80 per share. | Direct | 26,600 | Apr 14, 2025 |
| TESSARI EBEN Chief Operating Officer | Sale at price 20.19 - 20.74 per share. | Direct | 245,812 | Apr 14, 2025 |
| MEGNA MICHAEL R Officer | -- | Direct | -- | Apr 7, 2025 |
| PATEL SANJIV K Chief Executive Officer | -- | Direct | -- | Apr 7, 2025 |
| PAOLINI JOHN F Officer | -- | Direct | -- | Apr 7, 2025 |
| RAGOSA MARK Chief Financial Officer | -- | Direct | -- | Apr 7, 2025 |
| MOAT ROSS Officer | -- | Direct | -- | Apr 7, 2025 |
| TESSARI EBEN Chief Operating Officer | -- | Direct | -- | Apr 7, 2025 |
| MEGNA MICHAEL R Officer | -- | Direct | -- | Apr 1, 2025 |
| PATEL SANJIV K Chief Executive Officer | -- | Direct | -- | Apr 1, 2025 |
| PAOLINI JOHN F Officer | -- | Direct | -- | Apr 1, 2025 |
| RAGOSA MARK Chief Financial Officer | -- | Direct | -- | Apr 1, 2025 |
| MOAT ROSS Officer | -- | Direct | -- | Apr 1, 2025 |
| TESSARI EBEN Chief Operating Officer | -- | Direct | -- | Apr 1, 2025 |
| RAGOSA MARK Chief Financial Officer | Conversion of Exercise of derivative security at price 12.97 per share. | Direct | 206,794 | Mar 20, 2025 |
| RAGOSA MARK Chief Financial Officer | Sale at price 23.11 per share. | Direct | 368,466 | Mar 20, 2025 |
| RAGOSA MARK Chief Financial Officer | Conversion of Exercise of derivative security at price 12.97 per share. | Direct | 263,849 | Mar 19, 2025 |
| RAGOSA MARK Chief Financial Officer | Sale at price 23.10 per share. | Direct | 469,923 | Mar 19, 2025 |
| MEGNA MICHAEL R Officer | -- | Direct | -- | Mar 14, 2025 |
| PATEL SANJIV K Chief Executive Officer | -- | Direct | -- | Mar 14, 2025 |
| PAOLINI JOHN F Officer | -- | Direct | -- | Mar 14, 2025 |
| MOAT ROSS Officer | -- | Direct | -- | Mar 14, 2025 |
| TESSARI EBEN Chief Operating Officer | -- | Direct | -- | Mar 14, 2025 |
| MEGNA MICHAEL R Officer | Conversion of Exercise of derivative security at price 11.10 per share. | Direct | 100,466 | Mar 12, 2025 |
| RAGOSA MARK Chief Financial Officer | Conversion of Exercise of derivative security at price 11.97 per share. | Direct | 435,373 | Mar 12, 2025 |
| MEGNA MICHAEL R Officer | Sale at price 22.45 per share. | Direct | 203,195 | Mar 12, 2025 |
| RAGOSA MARK Chief Financial Officer | Sale at price 22.25 per share. | Direct | 809,277 | Mar 12, 2025 |
| TESSARI EBEN Chief Operating Officer | Conversion of Exercise of derivative security at price 3.80 per share. | Direct | 26,600 | Mar 10, 2025 |
| TESSARI EBEN Chief Operating Officer | Sale at price 21.06 per share. | Direct | 261,334 | Mar 10, 2025 |
| TESSARI EBEN Chief Operating Officer | Conversion of Exercise of derivative security at price 3.80 per share. | Direct | 26,600 | Feb 10, 2025 |
| TESSARI EBEN Chief Operating Officer | Sale at price 19.57 per share. | Direct | 273,980 | Feb 10, 2025 |
| MEGNA MICHAEL R Officer | Stock Award(Grant) at price 16.00 per share. | Direct | 7,504 | Jan 15, 2025 |
| MOAT ROSS Officer | Stock Award(Grant) at price 16.00 per share. | Direct | 17,888 | Jan 15, 2025 |
| TESSARI EBEN Chief Operating Officer | Conversion of Exercise of derivative security at price 3.80 per share. | Direct | 26,600 | Jan 13, 2025 |
| TESSARI EBEN Chief Operating Officer | Sale at price 18.13 - 19.08 per share. | Direct | 255,413 | Jan 13, 2025 |
| TESSARI EBEN Chief Operating Officer | Conversion of Exercise of derivative security at price 1.59 per share. | Direct | 25,467 | Dec 16, 2024 |
| TESSARI EBEN Chief Operating Officer | Sale at price 20.44 per share. | Direct | 470,467 | Dec 16, 2024 |
| RAGOSA MARK Chief Financial Officer | Conversion of Exercise of derivative security at price 10.76 - 11.10 per share. | Direct | 235,235 | Dec 9, 2024 |
| RAGOSA MARK Chief Financial Officer | Sale at price 21.27 - 21.38 per share. | Direct | 593,997 | Dec 9, 2024 |
| RAGOSA MARK Chief Financial Officer | Conversion of Exercise of derivative security at price 10.76 per share. | Direct | 162,648 | Dec 5, 2024 |
| RAGOSA MARK Chief Financial Officer | Sale at price 21.25 - 21.45 per share. | Direct | 323,009 | Dec 5, 2024 |
| MEGNA MICHAEL R Officer | Conversion of Exercise of derivative security at price 11.10 per share. | Direct | 95,971 | Nov 29, 2024 |
| MEGNA MICHAEL R Officer | Sale at price 22.45 per share. | Direct | 194,103 | Nov 29, 2024 |
| TESSARI EBEN Chief Operating Officer | Conversion of Exercise of derivative security at price 1.59 per share. | Direct | 15,900 | Nov 18, 2024 |
| TESSARI EBEN Chief Operating Officer | Sale at price 21.04 per share. | Direct | 357,680 | Nov 18, 2024 |
| LEVY RICHARD S Director | -- | Direct | -- | Nov 7, 2024 |
| PATEL SANJIV K Chief Executive Officer | Conversion of Exercise of derivative security at price 1.59 per share. | Direct | 142,402 | Nov 6, 2024 |
| PATEL SANJIV K Chief Executive Officer | Sale at price 23.00 per share. | Direct | 2,059,903 | Nov 6, 2024 |
| TESSARI EBEN Chief Operating Officer | Conversion of Exercise of derivative security at price 1.59 per share. | Direct | 15,900 | Oct 15, 2024 |
Related Tickers
NBIX Neurocrine Biosciences, Inc.
107.24
+0.73%
AMPH Amphastar Pharmaceuticals, Inc.
24.50
+0.37%
HROW Harrow, Inc.
24.67
+0.08%
ETON Eton Pharmaceuticals, Inc.
16.49
+3.19%
CRDL Cardiol Therapeutics Inc.
1.1500
+6.48%
EOLS Evolus, Inc.
11.57
+2.30%
STX.L Shield Therapeutics plc
2.3500
0.00%
SOBI.ST Swedish Orphan Biovitrum AB (publ)
296.20
+1.37%
INDV Indivior PLC
11.75
+1.56%
AKBA Akebia Therapeutics, Inc.
2.4300
0.00%